Iodinated I 125 Albumin Injection
Albumin labeled with iodine-125.
» Iodinated I 125 Albumin Injection is a sterile, buffered, isotonic solution containing normal human albumin adjusted to provide not more than 37 megabecquerels (1 millicurie) of radioactivity per mL. It is derived by mild iodination of normal human albumin with the use of radioactive iodine (125I) to introduce not more than one gram-atom of iodine for each gram-molecule (60,000 g) of albumin.
Iodinated I 125 Albumin Injection contains not less than 95.0 percent and not more than 105.0 percent of the labeled amount of 125I as iodinated albumin, expressed in megabecquerels (microcuries or in millicuries) per mL at the time indicated in the labeling. Other forms of radioactivity do not exceed 3 percent of the total radioactivity. Its production and distribution are subject to federal regulations (see Biologics 
1041
and Radioactivity 821).
1041 and Radioactivity 821).
Packaging and storage—
Preserve in single-dose or in multiple-dose containers, at a temperature between 2
and 8.
and 8.
Labeling—
Label it to include the following, in addition to the information specified for Labeling under Injections 1: the date of calibration; the amount of 125I as iodinated albumin, expressed as total megabecquerels (microcuries or millicuries), and concentration as megabecquerels (microcuries or millicuries) per mL on the date of calibration; the expiration date; and the statement “Caution—Radioactive Material.” The labeling indicates that in making dosage calculations, correction is to be made for radioactive decay, and also indicates that the radioactive half-life of 125I is 60 days.
1: the date of calibration; the amount of 125I as iodinated albumin, expressed as total megabecquerels (microcuries or millicuries), and concentration as megabecquerels (microcuries or millicuries) per mL on the date of calibration; the expiration date; and the statement “Caution—Radioactive Material.” The labeling indicates that in making dosage calculations, correction is to be made for radioactive decay, and also indicates that the radioactive half-life of 125I is 60 days.
Radionuclide identification (see Radioactivity 821)—
Its gamma-ray spectrum is identical to that of a specimen of 125I of known purity that exhibits a major photopeak having an energy of 0.0355 MeV.
821)—
Its gamma-ray spectrum is identical to that of a specimen of 125I of known purity that exhibits a major photopeak having an energy of 0.0355 MeV.
Bacterial endotoxins 85—
The limit of endotoxin content is not more than 175/V USP Endotoxin Unit per mL of the Injection, when compared with the USP Endotoxin RS, in which V is the maximum recommended total dose, in mL, at the expiration date or time.
85—
The limit of endotoxin content is not more than 175/V USP Endotoxin Unit per mL of the Injection, when compared with the USP Endotoxin RS, in which V is the maximum recommended total dose, in mL, at the expiration date or time.
pH 791:
between 7.0 and 8.5.
791:
between 7.0 and 8.5.
Radiochemical purity—
Place a measured volume, diluted with a suitable diluent so that it provides a count rate of about 20,000 counts per minute, about 25 mm from one end of a 25- × 300-mm strip of chromatographic paper (see Chromatography 621), and allow to dry. Develop the chromatogram over a period of about 4 hours by ascending chromatography, using dilute methanol (7 in 10), and air-dry. Determine the radioactivity distribution by scanning the chromatogram with a suitable collimated radiation detector: not less than 97.0% of the total activity is found as albumin (at the point of application).
621), and allow to dry. Develop the chromatogram over a period of about 4 hours by ascending chromatography, using dilute methanol (7 in 10), and air-dry. Determine the radioactivity distribution by scanning the chromatogram with a suitable collimated radiation detector: not less than 97.0% of the total activity is found as albumin (at the point of application).
Other requirements—
It meets the requirements under Biologics 1041 and under Injections 1, except that it is not subject to the recommendation on Volume in Container. It meets all other applicable requirements of the FDA.
1041 and under Injections 1, except that it is not subject to the recommendation on Volume in Container. It meets all other applicable requirements of the FDA.
Assay for radioactivity—
Using a suitable counting assembly (see Selection of a Counting Assembly under Radioactivity 821), determine the radioactivity, in MBq (µCi) per mL, of Injection by use of a calibrated system as directed under Radioactivity 821.
821), determine the radioactivity, in MBq (µCi) per mL, of Injection by use of a calibrated system as directed under Radioactivity 821.
Auxiliary Information—
Please check for your question in the FAQs before contacting USP.
| Topic/Question | Contact | Expert Committee |
| Monograph | Ian DeVeau, Ph.D.
Director, Veterinary Drugs and Radiopharmaceuticals 1-301-816-8178 |
(RMI05) Radiopharmaceuticals and Medical Imaging Agents 05 |
| Reference Standards | Lili Wang, Technical Services Scientist 1-301-816-8129 RSTech@usp.org |
|
| 85 |
Radhakrishna S Tirumalai, Ph.D.
Senior Scientist 1-301-816-8339 |
(MSA05) Microbiology and Sterility Assurance |
USP32–NF27 Page 2655